Author

E. Heilmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 2 Organism:virus· 2 Organism:human· 1

Frequent Co-Authors

D. von Laer· 3 shared F. Costacurta· 3 shared S. A. Moghadasi· 2 shared A. Dodaro· 1 shared A. Heberle· 1 shared A. Khalil· 1 shared A. Sauerwein· 1 shared A. Volland· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

D. von Laer

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system

F. Costacurta, A. Dodaro, D. Bante, H. Schoeppe, B. Sprenger, S. A. Moghadasi, J. Fleischmann, M. Pavan, D. Bassani, S. Menin, S. Rauch, L. Krismer, A. Sauerwein, A. Heberle, T. Rabensteiner, , E. Heilmann

This study identifies and characterizes SARS-CoV-2 Mpro mutations conferring resistance to nirmatrelvir using a VSV-based system and biochemical assays.

bioRxiv · Sep 22, 2023Microbiology

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

S. A. Moghadasi, E. Heilmann, A. Khalil, C. Nnabuife, F. Kearns, C. Ye, S. N. Moraes, F. Costacurta, M. Esler, H. Aihara, D. von Laer, L. Martinez-Sobrido, T. Palzkill, R. E. Amaro, R. Harris

The paper identifies SARS-CoV-2 variants resistant to protease inhibitors nirmatrelvir and ensitrelvir, showing pre-existing resistance and potential for spread.

bioRxiv · Aug 7, 2022Microbiology

SARS-CoV-2 3CLpro mutations confer resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-function system

E. Heilmann, F. Costacurta, A. Volland, D. von Laer

The paper identifies SARS-CoV-2 3CLpro mutations that confer resistance to Paxlovid using a VSV-based system and finds these mutations already exist in viral sequences.

bioRxiv · Jul 2, 2022 · PreprintMicrobiology